Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 16/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 10/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 8/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.73 |
| ▸ | PGR | P06401 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.68 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23851086 | 1.00 | ESR1 (1.00) | ESR1ESR2CYP19A1PTGS2PGR | |
| SCHEMBL7723356 | 1.00 | ESR1 (1.00) | ESR1ESR2CYP19A1PTGS2PGR | |
| SCHEMBL5354177 | 1.00 | ESR1 (1.00) | ESR1ESR2CYP19A1PTGS2PGR | |
| SCHEMBL639225 | 1.00 | ESR1 (1.00) | ESR1ESR2CYP19A1PTGS2PGR | |
| SCHEMBL5354173 | 1.00 | ESR1 (1.00) | ESR1ESR2CYP19A1PTGS2PGR | |
| Phenol SCHEMBL7723405 | 0.98 | ESR1 (0.96) | ESR1ESR2CYP19A1PTGS2PGR | |
| Phenol SCHEMBL10796314 | 0.98 | ESR1 (0.96) | ESR1ESR2CYP19A1PTGS2PGR | |
| Phenol SCHEMBL10796309 | 0.98 | ESR1 (0.96) | ESR1ESR2CYP19A1PTGS2PGR | |
| SCHEMBL13524705 | 0.93 | ESR1 (0.86) | ESR1ESR2CYP19A1PTGS2PGR | |
| SCHEMBL9451158 | 0.91 | ESR1 (0.83) | ESR1ESR2CYP19A1PTGS2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113347965-B | TGF-beta inhibitors and prodrugs | 生物医学研究机构基金会 | 2025-02-18 | — | — | CN | disclosed |
| EP-4311546-A1 | COMBINATION THERAPY FOR MYOPATHIES | Dynacure (FR) | 2024-01-31 | — | — | EP | disclosed |
| US-20220089600-A1 | TGFß INHIBITOR AND PRODRUGS | FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA) (ES) | 2022-03-24 | — | — | US | disclosed |
| EP-3883556-A2 | TGF? INHIBITOR AND PRODRUGS | Fundació Institut de Recerca Biomèdica IRB (Barcelona) (ES) | 2021-09-29 | — | — | EP | disclosed |
| CN-113347965-A | TGF-beta inhibitors and prodrugs | 生物医学研究机构基金会 | 2021-09-03 | — | — | CN | disclosed |
| WO-2006005856-A1 | USE OF POLYPHENOL ETHYLENE ORGANOMETALLIC DERIVATIVES FOR TREATING A NON-HORMONE DEPENDENT CANCER | CHASTENET, BERTRAND (FR) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089600-A1 | TGFß INHIBITOR AND PRODRUGS | TGFB1, TGFBR1, TGFBR2 | ESR1 2521/4885ESR2 876/4885CYP19A1 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.